![Haya Taitel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Haya Taitel
Directeur/Membre du Conseil chez ENTERA BIO LTD.
Fortune : 40 500 $ au 31/05/2024
Postes actifs de Haya Taitel
Sociétés | Poste | Début | Fin |
---|---|---|---|
ENTERA BIO LTD. | Directeur/Membre du Conseil | 07/06/2023 | - |
Independent Dir/Board Member | 07/06/2023 | - |
Historique de carrière de Haya Taitel
Anciens postes connus de Haya Taitel
Sociétés | Poste | Début | Fin |
---|---|---|---|
KADMON HOLDINGS, INC. | Corporate Officer/Principal | 01/01/2018 | 01/11/2021 |
Formation de Haya Taitel
Temple University School of Pharmacy | Graduate Degree |
The Hebrew University of Jerusalem | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 3 |
Israël | 3 |
Opérationnelle
Corporate Officer/Principal | 1 |
Graduate Degree | 1 |
Undergraduate Degree | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
ENTERA BIO LTD. | Health Technology |
Entreprise privées | 1 |
---|---|
Kadmon Holdings, Inc.
![]() Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
- Bourse
- Insiders
- Haya Taitel
- Expérience